ABSCH | Access and Benefit-Sharing Clearing-House
The Access and Benefit-sharing Clearing-House (ABSCH) is a platform for exchanging information on access and benefit-sharing and is a key tool to facilitate the implementation of the Nagoya Protocol. Learn more

Announcements


23 Jan 2023
 
Webinar: Overview of new and improved clearing-house features

31 January 2023, 09:00 AM to 10:00 AM EST

17 Jan 2023
 
Nomination of experts

Parties and observers are invited to nominate experts to participate in the ad hoc technical expert group on indicators for the Kunming-Montreal Global Biodiversity Framework

17 Dec 2022
 

Parties to the Nagoya Protocol

JavaScript chart by amCharts 3.21.6
Disclaimer
Loading...

National records


Recently published
26 Jan 2023 1-10

ABSCH-IRCC-VN-243508-1

Checkpoint Communiqué Japan absch-cpc-jp-262985-2
20 Jan 2023 ABS Permit N°00019/MINEPDED/CNA/NP-ABS/ABS-FP

Roots of the plant Echinops giganteus

20 Jan 2023 ABS Permit N°00020/MINEPDED/CNA/NP-ABS/ABS-FP

Exploitation of genetic resources of leaves, stem bark and root of Xeroderris Stuhlmannii

20 Jan 2023 Ministère de l'Environnement, de la Protection de la Nature et du Développement Durable (MINEPDED)

Le Ministère de l'Environnement, de la Protection de la Nature et du Développement Durable, Autorité Nationale Compétente, reçoit à travers le ABS-CH l'information concernant l'utilisation des ressources génétiques du Cameroun à des fins commerciales et non-commerciales.

Checkpoint Cameroon absch-cp-cm-262891-3

Reference records


Recently published
16 Jan 2023 CABI Switzerland's Best Practice for Access and Benefit Sharing Compliance

Contents 1. CABI’s ABS Policy and Best Practices 1 1.1 How CABI uses genetic material 1 1.2 Benefits CABI provides from its use of genetic material 2 2. Swiss legislation in relation to Access and Benefit Sharing (ABS) 2 3. CABI’s Best Practices and implementation in Switzerland 2 3.1 Accessing genetic resources for use (in situ) 3 3.2 Receiving biological and genetic resources from collaborators, collections or other providers (ex situ) 5 3.3 Transferring genetic material and/or resources outside of CABI 5 3.4 Enforcement and compliance 5 Annex 1: A glossary of useful terms and their definitions 6 Annex 2. Decision tree outlining the general steps of the CABI best practice. 8 Annex 3. CABI genetic resources database with an example entry 9 Annex 4. CABI generic MTA for supply of genetic resources 10

17 Dec 2022 BROGOTA PROJECT ABS AROUND THE WORLD: The Brazilian law contrasted with international regulations (Dec 2022)

New updated edition of this comprehensive global survey of national ABS regulations, highlights the continuous progress in the establishment and implementation of national ABS regulations around the world.

Virtual Library Resource absch-vlr-scbd-262696-3
12 Dec 2022 Wellcome Sanger Institute Best Practice - the Nagoya Protocol and Access and Benefit Sharing (ABS)

This document has been produced in order to provide assurance to Nagoya Protocol member states, regulators, researchers, collaborators and peers, that the Wellcome Sanger Institute has initiated and carries out appropriate processes and procedures to enable compliance with global Access and Benefit Sharing (hereafter; ABS) measures and compliance with the UK ABS legislation5 implementing the Nagoya Protocol1 for scientific research undertaken. Within this document are the tools, processes and procedures, comprising Institute policy, that when employed correctly staff and associates of the Wellcome Sanger Institute can be confident that they are conducting their research in accordance with the UK ABS legislation and in turn, ABS legislation in force globally.

06 Dec 2022 OGIEK COMMUNITY BIO-CULTURAL PROTOCOL (OC-BCP)

The Bio-Cultural Community Protocol of the Ogiek peoples provides an insight into important social and cultural values of our people. It highlights and documents our traditional knowledge, way of life, customary laws and the key elements of Free Prior Informed Consent (FPIC) when engaging with external actors such as government, research Institutions, pharmaceutical companies and other private investors.